Enliven Therapeutics, Inc. 8-K

What Happened
Enliven Therapeutics, Inc. announced that following its Annual Meeting of Stockholders on June 9, 2026, stockholders approved an amendment to the company’s certificate of incorporation and the company filed a Certificate of Amendment effective June 9, 2026. The amendment increases authorized shares of Common Stock from 100,000,000 to 200,000,000 and sets total authorized shares at 210,000,000 (200,000,000 common; 10,000,000 preferred).

Key Details

• Annual Meeting held and vote taken on June 9, 2026; Certificate of Amendment filed and effective the same day.
• Authorized Common Stock increased from 100,000,000 to 200,000,000 shares.
• Total authorized shares now 210,000,000 (200,000,000 Common; 10,000,000 Preferred).
• Certificate of Amendment is filed as Exhibit 3.1 to the Form 8-K; the filing was signed by President & CEO Richard Fair.

Why It Matters
Increasing authorized shares gives the company legal capacity to issue more common stock in the future, which can be used for fundraising, acquisitions, or employee equity programs. For investors, this change creates the potential for dilution if the company chooses to issue new shares; it also provides the company flexibility to raise capital or pursue growth transactions. Shareholders should watch future filings (e.g., equity offerings, registration statements) for any actual issuances.